Targeting CD22 as a strategy for treating systemic autoimmune diseases

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 953-959

  Dörner, Thomas ^a   Goldenberg, David M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Autoimmune diseases; B cells; CD22; Epratuzumab

Indexed keywords

ABETIMUS; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BELIMUMAB; CD22 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXCHLORPHENIRAMINE MALEATE; DIPHENHYDRAMINE; EPRATUZUMAB; HYDROXYCHLOROQUINE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PARACETAMOL; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG; VELTUZUMAB;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CLINICAL TRIAL; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLUSHING; HUMAN; HYPERSENSITIVITY REACTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NONHODGKIN LYMPHOMA; PAIN; PLASMA HALF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VOMITING;

EID: 36448931656     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Boumpas DT, Austin HA, Vaughn EM, et al. 1992. Controlled trial of pulse methylprednisolone versus 2 regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, 340:741-5.
2. Carnahan J, Stein R, Qu ZX, et al. 2007. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol, 44:1331-41.
3. Carnahan J, Wang P, Kendall R, et al. 2003. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res, 9:3982S-90S.
4. Chan TM, Li FK, Tang CSO, et al. 2000. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med, 343:1156-62.
5. Chaouchi N, Vazquez A, Galanaud P, et al. 1995. B-cell antigen receptor-mediated apoptosis - importance of accessory molecules CD19 and CD22, and of surface IgM crosslLinking. J Immunol, 154:3096-104.
6. Contreras G, Lenz O, Roth D. 2004. Sequential therapies for proliferative lupus nephritis - The authors reply. N Engl J Med, 350:2519-20.
7. De Vita S, Zaja F, Sacco S, et al. 2002. Efficacy of selective B-cell blockade in the treatment of rheumatoid arthritis - Evidence for a pathogenetic role of B-cells. Arthritis Rheum, 46:2029-33.
8. Doody GM, Justement LB, Delibrias CC, et al. 1995. A role in B-cell activation for CD22 and the protein-tyrosine-phosphatase Shp. Science, 269:242-4.
9. Dörken B, Moldenhauer G, Pezzutto A, et al. 1986. Hd39 (B3), A B-lineage-restricted antigen whose cell-surface expression is limited to resting and activated human lymphocytes-B. J Immunol, 136:4470-9.
10. Dörner T. 2006. Crossroads of B-cell activation in autoimmunity: Rationale of targeting B-cells. J Rheumatol, 33:3-11.
11. Dörner T, Burmester GR. 2003. The role of B-cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol, 15:246-52.
12. D⊣sorner T, Kaufmann J, Wegener WA, et al. 2006. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther, 8:000-000.
13. Dörner T, Lipsky PE. 2006. Signalling pathways in B-cells: Implications for autoimmunity. Current Concepts in Autoimmunity and Chronic Inflammation, 305:213-40.
14. Edwards JCW, Cambridge G. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B-lymphocytes. Rheumatology, 40:205-11.
15. Edwards JCW, Cambridge G. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol, 6:394-403.
16. Edwards JCW, Szczepanski L, Szechinski J, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 350:2572-81.
17. Engel P, Nojima Y, Rothstein D, et al. 1993. The same epitope on CD22 of B-lymphocytes mediates the adhesion of erythrocytes, T-lymphocytes and BlLymphocytes, neutrophils, and monocytes. J Immunol, 150:4719-32.
18. Engel P, Wagner N, Miller AS, et al. 1995. Identification of the ligand-binding domains of CD22, A member of the immunoglobulin super-family that uniquely binds a sialic acid-dependent ligand. J Exp Med, 181:1581-6.
19. Goldenberg DM. 2006. Epratuzumab in the therapy of oncological and immunological diseases. Exp Rev Anticancer Ther, 5:1341-53.
20. Jacobi AM, Goldenberg DM, Hiepe F, et al. 2007. Differential effects of epratuzumab on anti-Ig-induced proliferation of peripheral blood B-cells of SLE patients and normal subjects. Ann Rheum Dis. August 2 [Epub ahead of print].
21. Jacobson DL, Gange SJ, Rose NR, et al. 1997. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol, 84:223-43.
22. Kelm S, Pelz A, Schauer F, et al. 1994. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependeiit adhesion molecules of the immunoglobulin superfamily. Curr Biol, 4:965-72.
23. Keystone E. 2005. B-cell targeted therapies. Arthritis Res Ther, 7: S13-S18.
24. Leandro MJ, Edwards JC, Cambridge G, et al. 2002a. An open study of B-lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum, 46:2673-7.
25. Leandro MJ, Edwards JCW, Cambridge G. 2002b. Clinical outcome in 22 patients with rheumatoid arthritis treated with B-lymphocyte depletion. Ann Rheum Dis, 61:883-8.
26. Leonard JP, Coleman M, Ketas JC, et al. 2003. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol, 21:3051-9.
27. Leonard JP, Coleman M, Matthews JC, et al. 2002. Phase I/II trial epratuzumab (humanized anti-CD22 anti body) in non-Hodgkin's lymphoma (NHL). Blood, 100:358A.
28. Leung SO, Dion AS, Pellegrini MC, et al. 1995. Effect of Vk framework-1 glycosylation on the binding-affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as novel conjugation site. Int J Cancer, 60:534-8.
29. Leung SO, Shevitz J, Pellegrini MC, et al. 1994. Chimerization of LL2, a rapidly internalizing antibody specific for B-cell lymphoma. Hybridoma, 13:469-76.
30. Lipsky PE. 2001. Systemic lupus erythematosus: autoimmune disease of β-cell hyperactivity. Nat Immunol, 2:764-6
31. Martin F, Chan AC. 2006. B-cell immunobiology in disease: evolving concepts from the clinic. Ann Rev Immunol, 24 467-96.
32. Mitchison NA, Wedderburn LR. 2000. B-cells in autoimmunity. Proc Natl Acad Sci USA, 97:8750-1.
33. Nitschke L. 2005. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol, 17:290-7.
34. Nitschke L, Carsetti R, Ocker B, et al. 1997. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol, 7:133-43.
35. O'Keefe TL, Williams GT, Batista FD, et al. 1999. Deficiency in CD22, a B-cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med, 189:1307-13.
36. Oligino TJ, Dalrymple SA. 2003. Targeting B-cells for the treatment of rheumatoid arthritis. Arthritis Res Ther, 5:S7-S11.
37. Otipoby KL, Andersson KB, Draves KE, et al. 1996. CD22 regulates thymus-independent responses and the lifespan of B-cells. Nature, 384:634-7.
38. Park YW, Pryshchep S, Seyler TM, et al. 2005. B-cells as a therapeutic target in autoimmune diseases. Expert Opin Ther Targets, 9:431-45.
39. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, et al. 1989. Two new monoclonal-antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res, 49:4568-77.
40. Pijpe J, Bootsma H, Van Imhoff G, et al. 2004. Rituximab (anti-CD20) for the treatment of primary Sjogren's syndrome. Arthritis Rheum, 50:S575.
41. Pijpe J, van Imhoff GW, Spijkervet FKL, et al. 2005. Rituximab treatment in patients with primary Sjogren's syndrome. Arthritis Rheum, 52:2740-50.
42. Radbruch A, Muehlinghaus G, Luger EO, et al. 2006. Competence and competition: the challenge of becoming a to long-lived plasma cell. Nat Rev Immunol, 6:741-50.
43. Reff ME, Carrier K, Chambers KS, et al. 1994. Depletion of B-cells in-vivo by a chimeric mouse-human monoclonal-antibody to CD20. Blood, 83:435-45.
44. Sato S, Miller AS, Inaoki M, et al. 1996. CD22 is both a positive and negative regulator of B-lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice. Immunity, 5:551-62.
45. Shih LB, Lu HHZ, Xuan H, et al. 1994. Internalization and intracellular processing of an anti B-cell lymphoma monoclonal antibody, LL2. Int J Cancer, 56:538-45.
46. Stamenkovic I, Seed B. 1990. The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature, 345:74-7.
47. Stasi R, Pagano A, Stipa E, et al. 2001. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood, 98:952-7.
48. Stein R, Belisle E, Hansen HJ, et al. 1993. Epitope specificity of the anti-(B-cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother, 37:293-8.
49. Stein F, Qu ZX, Chen S, et al. 2004. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res, 10:2868-78.
50. Steinfeld SD, Tant L, Burmester GR, et al. 2006. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogrens's syndrome: an open-label phase I/II study. Arthritis Res Ther, 8:000-000.
51. Steinfeld SD, Youinou P. 2006. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Exp Opin Biol Ther, 6:943-9.
52. Tahir H, Rohrer J, Bhatia A, et al. 2005. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology, 44:561-2.
53. Tedder TF, Poe JC, Haas KM. 2005a. CD22: A multifunctional lectin that regulates B-lymphocyte survival and signal transduction. Glycobiology, 15:1197.
54. Tedder TF, Poe JC, Haas KM. 2005b. CD22: A multifunctional receptor that regulates B-lymphocyte survival and signal transduction. Adv Immunol, 88:1-50.
55. Teeling JL, French RR, Cragg MS, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 104:1793-800.
56. Tuscano JM, Riva A, Toscano SN, et al. 1999. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood, 94:1382-92.
57. Uchida JJ, Hamaguchi Y, Oliver JA, et al. 2004. The innate mononuclear phagocyte network depletes B-lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med, 199:1659-69.
58. Viau M, Zouali M. 2005. B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol, 114:17-26.
59. Voulgarelis M, Dafni UG, Isenberg KA, et al. 1999. Malignant lymphoma in primary Sjogren's syndrome - A multicenter, retrospective, clinical study by the European concerted action on Sjogren's syndrome. Arthritis Rheum, 42:1765-72.
60. William J, Euler C, Primarolo N, et al. 2006. B-cell tolerance checkpoints that restrict pathways of antigen-driven differentiation. J Immunol, 176:2142-51.
61. Wilson GL, Fox CH, Fauci AS, et al. 1991. CDNA cloning of the B-cell membrane-protein CD22 - A mediator of B-B-cell interactions. J Exp Med, 173:137-46.